Carregant...
Administration of a Sigma Receptor Agonist Delays MCAO-Induced Neurodegeneration and White Matter Injury
Many pharmacological treatments for stroke have afforded protection in rodent models but failed to show efficacy in clinical trials. This discrepancy may be due to the lack of long-term functional studies. Previously, delayed administration of the sigma receptor agonist 1,3-di-o-tolylguanidine (DTG)...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2885737/ https://ncbi.nlm.nih.gov/pubmed/20563232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12975-009-0005-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|